Table 5.

Baseline characteristics and treatment effects between Group 2 and VIBRANT 52weeks trial.

	Group 3 (first Bevacizumab and then Aflibercept or all Aflibercept) n = 15	VIBRANT 52weeks trial N = 91
Average amount of IVI	3.73 (1.58)	9.0 (1.8)	P < .0001*
Portion of patients with improvement < 15ETDRS letters(%)	2 (13.33%)	32 (35.16%)	P = .22†
Portion of patients with improvement ≧ 15 ETDRS letters(%)	12 (80%)	52 (57.14%)
Portion of patients with ETDRS letters loss(%)	1 (6.67%)	7 (7.7%)
Average initial CRT, μm, mean(SD)	516.33 (130.41)	–‡	–‡
Average CRT improvement, μm, mean(SD)	237.67 (135.46)	283.9 (–)‡	–‡

^*Two sample t test.

^†Fisher exact test.

^‡Not available data for further calculation.

CRT = central retinal thickness, IVI = intravitreal injection, SD = standard deviations.